Pharmaceutics International

Executive Summary

Pharmaceutics International (Pii) is a US-based contract development and manufacturing organization (CDMO) specialized in complex drug product formulation and manufacturing, particularly for parenteral and oral dosage forms involving potent compounds and sensitive molecules. Founded in 1981 and headquartered in Baltimore, the company was acquired by Jabil Inc. in February 2025, a move that combines Pii's pharmaceutical expertise with Jabil's global manufacturing scale and operational capabilities. This acquisition positions Pii to expand its service offerings and client base, leveraging Jabil's resources to enhance capacity and technology. As a private entity, Pii does not have public financial disclosures, but the partnership with Jabil provides a strong foundation for growth in the CDMO market, which is driven by increasing demand for complex drug formulations and outsourcing by pharmaceutical companies. The executive summary highlights Pii's strategic advantage in specialized formulation and its potential for expansion under Jabil's ownership, targeting pharmaceutical and biotech clients seeking reliable partners for challenging drug development and manufacturing projects.

Upcoming Catalysts (preview)

• Q3 2026Integration with Jabil's Manufacturing Network80% success
• Q4 2026New Capacity Expansion Announcement60% success
• Q2 2026Major Contract Win with Top Pharma Client50% success